Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elevate-CKD
2025-523994-41-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 39
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Elecoglipron + background dapagliflozin with Placebo + background dapagliflozin (2 arms). Primary endpoint: Composite renal outcome or all-cause mortality. Planned start Aug 2026; status: authorised.
02
Drugs
elecoglipron
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2025-523994-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523994-41-00.